ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
2,2,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
2,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2,4,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
2,5,Pericarditis,Noninfectious pericarditis,Pericardial disorders,Card,N
3,1,Cerebrovascular disorder,Central nervous system vascular disorders NEC,Central nervous system vascular disorders,Nerv,N
3,2,Lung adenocarcinoma,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
3,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
4,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
5,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
5,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
6,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
6,2,Non-small cell lung cancer,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,Y
7,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
7,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
8,1,Hair growth abnormal,Pilar disorders NEC,Skin appendage conditions,Skin,N
8,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
8,3,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
9,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
9,2,Volvulus,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
10,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
10,2,Alopecia,Alopecias,Skin appendage conditions,Skin,N
10,3,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
10,4,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
10,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
10,6,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
10,7,Tooth discolouration,Dental surface disorders,Dental and gingival conditions,Gastr,N
11,1,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
11,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
11,3,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
11,4,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
11,5,Neurological decompensation,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
11,6,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
12,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
13,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
13,2,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
13,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
14,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
14,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
14,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
14,4,Neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
15,1,Movement disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
15,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
16,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
16,2,Large intestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
16,3,Peritoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
17,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
17,2,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
17,3,Lung neoplasm malignant,Respiratory tract and pleural neoplasms malignant cell type unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
17,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
17,5,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
18,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
19,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
19,2,Non-small cell lung cancer,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
19,3,Oesophageal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
19,4,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
19,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
20,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
20,2,Colonic abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
20,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
20,4,Diverticulitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
20,5,Diverticulitis intestinal haemorrhagic,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
20,6,Intra-abdominal fluid collection,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
20,7,Large intestine perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
21,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
22,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
22,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
22,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
23,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
23,2,Neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
24,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
24,2,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
24,3,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,Y
24,4,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
25,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
25,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
25,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
25,4,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
25,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
26,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
26,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
26,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
27,1,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
27,2,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
27,3,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
28,1,Corneal deposits,"Corneal structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
29,1,Headache,Headaches NEC,Headaches,Nerv,N
29,2,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
29,3,Neurocysticercosis,Cestode infections,Helminthic disorders,Infec,N
30,1,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
31,1,Supraventricular tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
32,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
32,2,Headache,Headaches NEC,Headaches,Nerv,N
32,3,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
32,4,Metastases to kidney,Metastases to specified sites,Metastases,Neopl,N
32,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
33,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
33,2,Lipase increased,Digestive enzymes,Gastrointestinal investigations,Inv,N
33,3,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
33,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
34,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
34,2,Neutrophil count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
35,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
35,2,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
35,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
35,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
36,1,Lung adenocarcinoma,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
36,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
36,3,Therapy partial responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
37,1,Cornea verticillata,"Corneal structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
38,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
38,2,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
39,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
39,2,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
39,3,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
40,1,Cardiotoxicity,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
40,2,Lung adenocarcinoma stage IV,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
40,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
40,4,Metastases to uterus,Metastases to specified sites,Metastases,Neopl,N
41,1,Cardiotoxicity,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
41,2,Haematotoxicity,Haematological disorders,Haematological disorders NEC,Blood,N
41,3,Nephropathy toxic,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
42,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
